← Back to Home

Selective T-cell activation: investigational cancer drug invikafusp shows tumor shrinkage in early trial

Invikafusp alfa showed preliminary anticancer signals in patients with advanced cancer who had limited options after multiple treatments; however, the 59.3% disease control rate came from 27 patients receiving the optimal dose, and long-term benefit remains to be established.

By SURL BioNews

How to reawaken the body's ability to fight cancer when it no longer responds even to immunotherapy remains a difficult clinical challenge. The experimental drug invikafusp alfa aims to selectively activate a small subset of T cells. In its first-in-human trial, some patients who had undergone multiple lines of treatment experienced tumor shrinkage, providing preliminary clinical evidence for this approach.

The START-001 trial, sponsored by Marengo Therapeutics, reported phase 1 dose-escalation results from 34 patients and preliminary phase 2 data from 18 patients. Researchers from the US National Institutes of Health (NIH), Mass General Brigham, and other institutions participated in the study. The findings were published in Nature Medicine on October 23 and presented at the 2026 European Society for Medical Oncology Congress.

The denominators behind the efficacy figures require careful distinction: among 27 patients who received the optimal dose across the two phases, 16 achieved disease control, a rate of 59.3%; four had target tumor shrinkage of more than 30%, representing 14.8%. Disease control includes tumor shrinkage or stable disease, so the nearly 60% figure cannot be interpreted as a tumor shrinkage rate or applied directly to all participants.

According to the NIH, among the patients who experienced tumor shrinkage, two had metastatic colorectal cancer and were receiving invikafusp as their seventh line of treatment; another had stage IV non-small cell lung cancer and had previously received multiple therapies, including immune checkpoint inhibitors. Marengo further noted that cases with confirmed responses included microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. However, responses in a small number of cases are insufficient to conclude that patients across an entire cancer type could benefit.

Invikafusp is a protein drug that promotes the expansion of two T-cell subsets, Vβ6/Vβ10, through synergistic binding to the T-cell receptor and the interleukin-2 receptor, with the aim of focusing immune stimulation on specific cell populations. The study observed increases in the targeted T cells in both blood and tumors. However, the NIH also emphasized that immune activation does not always translate into measurable clinical efficacy, and changes in cell numbers cannot replace evidence of actual patient benefit.

Regarding safety, Mass General Brigham stated that treatment-related side effects were mostly mild to moderate. According to the sponsor's announcement, cytokine release syndrome was predominantly low-grade, with no treatment-related deaths or cases of immune effector cell-associated neurotoxicity syndrome (ICANS). The study also selected a recommended phase 2 dose, and the maximum tolerated dose was not reached. These results support further research, but a small early-stage trial still cannot readily rule out rare or late-emerging risks.

The current data primarily address whether this selective approach to stimulating T cells can produce the intended effects in humans and whether anticancer signals emerge. Determining which patients might achieve longer disease control and whether survival improves will require larger studies with longer follow-up and appropriate comparisons. The phase 2 expansion trial remains ongoing. The next key step is to translate the observed immune changes into reproducible and durable clinical benefits.

References

  1. Cancer Health
  2. Mass General Brigham
  3. National Institutes of Health
  4. Marengo Therapeutics via PR Newswire